Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus DICYCLOMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus DICYCLOMINE HYDROCHLORIDE.
DETROL vs DICYCLOMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
10-20 mg orally 3-4 times daily
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Category C
Category A/B
Anticholinergic
Anticholinergic